Press release
Herpes Zoster (Shingles) Market - Current Scenario and Forecast 2024
Herpes Zoster also known as zoster or shingles is a painful contagious viral disease which is characterized by blisters in limited area and painful skin rashes. These blisters full of liquid and pus appear on either side of the body or face, left or right in a single stripe. This disease is caused by varicella zoster virus which develops short lived or acute illness named as chickenpox that is usually seen in young adults and children. Patients who never got chickenpox cannot get shingles. The onset of the infection caused by this virus is also seen years after the episode of chicken pox has been resolved as at that time varicella virus is not eliminated completely from the body. Though shingles can develop at any age, people who had chickenpox before the age of 1 and people who are above the age of 60 are more likely to develop this condition. Senior citizens (aged 60 and above). People whose immune system is weakened by medications or disease are also likely to develop this condition. Diagnosis usually depends on the signs and synonyms of the person. After the resolution of chicken pox herpes virus remains in latent phase in nerve cell bodies or in non-neuronal satellite cells of the cranial nerve, autonomic ganglia or dorsal root.However, after decades the virus is again activated due to weakening of immune system that might occur owing to fever, aging or stress. The virus may spread from one nerve ganglia to another of an affected skin area. Headache, fever, nausea and malaise are the earlier symptoms of herpes zoster which may also result in incorrect diagnosis. However, these symptoms may be followed by itching, burning pain, oversensitivity or numbness. Over this area rash or band strip is developed which turns into blisters few days later. This blister is filled with fluid that usually takes 2 weeks to 4 weeks to recover.
Request Brochure of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14999
Shingles is most common in old age people as compared to young age generation because they have weak immune system that might develop due to fever, stress, certain medications or injury. Similarly, people undergoing chemotherapy or radiation therapy or taking medications such as steroids that weaken immune system are more prone to be victim of shingles infection. According to the Centers for Disease Control and prevention (CDC) in the United States every year more than 1 million cases of herpes zoster are estimated. Similarly, approximately 1 out of every 3 people in the United States develops herpes zoster once in their lifetime. Thus, for the diagnosis of herpes zoster laoboratory tests are performed which majorly detects VZV-specific IgM antibody in the blood. This antibody occurs in the blood stream only during the time of chicken pox or herpes zoster. After the diagnosis of the disease certain medications also prescribed for the treatment that include antiviral medications (acyclovir, famciclovir and valcyclovir), narcotic medications, anti-inflammatory medications, antihistamines (Benadryl), anticonvulsants or zostrix cream and others.
Furthermore, for the prevention of viral infection vaccines are prescribed to prevent an individual from developing severe shingles complications or symptoms. Zostavax is a live vaccine that is marketed for VZV. These vaccines are recommended by the Advisory Committee on Immunization Practices (ACIP), U.S. to reduce the risk of shingles and its associated pain in people aged over 60 years. In England annual incidence of shingles for those aged 70 years to 79 years is anticipated to be around 800 to 900 cases per 100,000 people.
Geographically, North America is the leading geography followed by the European market. Market growth of these regions is accounted due to presence of large base of population suffering from shingles. Asia-Pacific and Rest of the world region in the future are expected to emerge as fastest growing economies in this market.
Report Details @ https://www.transparencymarketresearch.com/herpes-zoster-market.html
Herpes Zoster Market Key Players
Major players that are involved in the development of therapeutics against shingles include Astellas Pharma, Inc. GlaxoSmithKline PLC, Foamix Ltd., Epiphany Biosciences and Merck & Co.
Request Pre Book @ https://www.transparencymarketresearch.com/checkout.php?rep_id=14999<ype=S
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: www.transparencymarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Herpes Zoster (Shingles) Market - Current Scenario and Forecast 2024 here
News-ID: 915696 • Views: …
More Releases from Transparency Market Research
Neuromorphic Chip Market to Reach USD 2.3 Billion by 2034, Driven by Explosive A …
The global Neuromorphic Chip Market is entering a defining phase of exponential growth, propelled by a surge in artificial intelligence (AI) applications, edge computing expansion, and rapid advancements in next-generation semiconductor technologies. According to the latest industry analysis, the market-valued at US$ 56.2 Mn in 2023-is projected to expand at an extraordinary CAGR of 40.1% from 2024 to 2034, reaching an estimated US$ 2.3 Bn by 2034.
Examine key highlights and…
Neuroprotection Market Surges Toward USD 60.1 Bn by 2031 as Global Neurological …
The global Neuroprotection Market continues to gain unprecedented momentum as healthcare systems worldwide intensify their focus on combating neurological disorders. With a valuation of US$ 31.6 Bn in 2022, the market is on track to reach US$ 60.1 Bn by 2031, expanding at a robust 7.5% CAGR during the forecast period. The rise in dementia, stroke, Parkinson's, epilepsy, and multiple sclerosis-combined with aging demographics and a surge in sedentary lifestyles-has…
Neuroregeneration Therapy Market Set to Reach USD 64.8 Bn by 2034, Driven by Inn …
The global neuroregeneration therapy market continues to chart steady, sustained growth. The increasing incidence of neurological disorders-including Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, stroke, diabetic neuropathy, and spinal cord injuries-is significantly influencing market expansion. In 2023, the market was worth US$ 37.0 Bn, demonstrating rising demand for treatments capable of repairing or regenerating damaged neural tissue.
Examine key highlights and takeaways from our Report in this sample -
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86322
With breakthroughs…
Neuroscience Market Set to Reach USD 41.6 Bn by 2031 Driven by Technological Adv …
The global neuroscience market stood at US$ 30.1 Bn in 2022, reflecting the significant technological and clinical potential of neurological research. Projected to grow at a CAGR of 3.7% from 2023 to 2031, the industry is expected to reach US$ 41.6 Bn by 2031. Rising prevalence of neurodegenerative diseases, advancements in neuroimaging, integration of artificial intelligence, and the emergence of brain-computer interfaces are shaping the next decade of neuroscience innovation.
Examine…
More Releases for Herpes
Unlocking Prosperity: Drugs for Herpes Labialis (Oral Herpes) Market Insights
Dive into the pulse of 𝐃𝐫𝐮𝐠𝐬 𝐟𝐨𝐫 𝐇𝐞𝐫𝐩𝐞𝐬 𝐋𝐚𝐛𝐢𝐚𝐥𝐢𝐬 (𝐎𝐫𝐚𝐥 𝐇𝐞𝐫𝐩𝐞𝐬) 𝐌𝐚𝐫𝐤𝐞𝐭 trends with Growth Market Reports latest report! Gain a competitive edge with our in-depth analysis, uncovering market dynamics, consumer behaviors, and strategic imperatives. Let our expertise guide your decision-making and drive success in the ever-evolving landscape. Navigate the trends shaping the landscape and emerge with actionable insights to drive your business forward. Our comprehensive analysis offers a strategic…
Market Mastery: Drugs for Herpes Labialis (Oral Herpes) Market Impact Beyond Exp …
𝐆𝐫𝐨𝐰𝐭𝐡 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭𝐬, a leading authority in Market analysis, has released an extensive report on the Drugs for Herpes Labialis (Oral Herpes) Market. Tailored for clients seeking new Market dimensions, in-depth product insights, revenue optimization, and strategic reviews of key players, the report provides a roadmap for Market exploration.
𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐭𝐡𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐃𝐫𝐮𝐠𝐬 𝐟𝐨𝐫 𝐇𝐞𝐫𝐩𝐞𝐬 𝐋𝐚𝐛𝐢𝐚𝐥𝐢𝐬 (𝐎𝐫𝐚𝐥 𝐇𝐞𝐫𝐩𝐞𝐬) 𝐑𝐞𝐩𝐨𝐫𝐭 𝐏𝐃𝐅 @ https://growthmarketreports.com/request-sample/7?utm=Openpr
𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐬 𝐛𝐲 𝐃𝐫𝐮𝐠𝐬 𝐟𝐨𝐫 𝐇𝐞𝐫𝐩𝐞𝐬 𝐋𝐚𝐛𝐢𝐚𝐥𝐢𝐬 (𝐎𝐫𝐚𝐥 𝐇𝐞𝐫𝐩𝐞𝐬)
𝐁𝐲 𝐏𝐫𝐨𝐝𝐮𝐜𝐭…
Herpes Simplex Virus Treatment Market - Unlocking Relief, Conquering Herpes: Red …
Newark, New Castle, USA - new report, titled Herpes Simplex Virus Treatment Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Herpes Simplex Virus Treatment market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Herpes Simplex Virus Treatment market. The report offers…
Herpes Labialis (Oral Herpes) Market SWOT Analysis by Key Players: BlueWillow Bi …
HTF Market Intelligence released a new research Study of 95 pages on title 'Herpes Labialis (Oral Herpes) - Global Clinical Trials Review, H1, 2021' with in-depth analysis, forecast and business moves. The study covers key regions that includes North America Country (United States, Canada), South America, Asia Country (China, Japan, India, Korea), Europe Country (Germany, UK, France, Italy), Other Country (Middle East, Africa, GCC) and important players such as GlaxoSmithKline…
Global Herpes Labialis (Oral Herpes) Drugs Market Future Analysis Report 2018-20 …
This report studies the global market size of Herpes Labialis (Oral Herpes) Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Herpes Labialis (Oral Herpes) Drugs in these regions.
This research report categorizes the global Herpes Labialis (Oral Herpes) Drugs market by players/brands, region, type and application. This report also studies the global market status, competition…
Drugs For Herpes Labialis (Oral Herpes) Market Demand, Overview, Price and Forec …
ReportBazzar has released its latest research-based report entitled ‘Drugs For Herpes Labialis (Oral Herpes)’ market. This report provides a holistic approach to the market growth with a detailed and precise analysis of the overall competitive scenario of the Drugs For Herpes Labialis (Oral Herpes) market. The report also provides a detailed analysis of key trends and latest technologies, playing a prominent role in the Drugs For Herpes Labialis (Oral Herpes)…
